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Abstract 
Review on HELLS, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: LSH, PASG, SMARCA6 
HGNC (Hugo): HELLS 
Location: 10q23.33 
Note 
HELLS (helicase, lymphoid specific) is a member 
of the SNF2 family of chromatin remodelling 
proteins that utilize ATP to alter the structure and 
packaging of chromatin (Jarvis et al., 1996). These 
changes in chromatin together with changes in 
other epigenetic mechanisms such as DNA  
methylation and histone modifications alter cellular 
processes such as transcription, mitosis, meiosis, 
and DNA repair.  
HELLS has been shown to be important for stem 
cell gene control, Hox gene control, DNA 
methylation, DNA repair, meiosis, and chromatin 
packaging of repetitive DNA (Dennis et al., 2001; 
Yan et al., 2003b; De La Fuente et al., 2006; Myant 
et al., 2008; Burrage et al., 2012). 
HELLS belongs to the SNF2 family of chromatin 
remodelling proteins.  
This group of proteins are involved in altering 
chromatin structure by hydrolyzing ATP and 
moving nucleosomes. HELLS has orthologues in 
mouse, Xenopus laevis, Danio rerio, Arabidopsis 
thaliana, and Saccharomyces cerevisiae among 
others.  
 
Figure 1. The HELLS gene is located on the long arm of human chromosome 10 at position 24.2. HELLS is found from 
base pair 94545767 to 94602871 base pair (GRCh38 assembly). Neighboring genes are shown. 
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Figure 2. The HELLS protein contains the helicase ATP binding and helicase C-terminal domains as identified by Prosite. It 
additionally contains a nuclear localization signal. 
 
 
The best studied is the mouse gene called Lsh 
(lymphoid specific helicase) that resides on a 
syntenic region of mouse chromosome 19 (Geiman 
et al., 1998). 
DNA/RNA 
Description 
The HELLS gene consists of 22 exons spanning 
57104 base pairs. It is highly expressed in 
embryonic stem cells, proliferating lymphoid 
cells/tissue, and germ cells. In stem cells, 
expression decreases upon differentiation. HELLS 
is additionally expressed at a lower level in many 
tissues of the developing embryo. In normal adult 
somatic tissue, expression is low with the exception 
of proliferating lymphocytes. 
Transcription 
The HELLS gene produces a transcript of 3163 bp. 
Ten alternatively spliced isoforms have been 
detected. The functional relevance of most of these 
splice variants is currently unknown. One, variant 1 
containing a 44 ntd insertion between exons 3 and 
4, creates an additional exon and has been 
associated with non-small cell lung cancer 
(NSCLC) (Yano et al., 2004). An additional 
variant, variant 9, contains a 75 ntd deletion in exon 
18 and has been associated with acute myelogenous 
leukemia an acute lymphoblastic leukemia (Lee et 
al., 2000). 
Pseudogene 
None. 
Protein 
Description 
HELLS protein consists of 838 amino acids with a 
predicted size of 97 kD. Since Lsh is a member of 
the SNF2 chromatin remodeling protein family, it 
contains the ATP binding and C-terminal helicase 
domains of this subfamily of helicases. 
Localisation 
Nuclear. 
Function 
HELLS functions as a chromatin remodeling family 
member linking multiple epigenetic mechanisms 
including histone modifications and DNA 
methylation (Dennis et al., 2001; Yan et al., 2003a; 
Yan et al., 2003b; Huang et al., 2004; Fan et al., 
2005; Zhu et al., 2006; Xi et al., 2007; Myant et al., 
2008). Knockout mice die perinatally with defects 
in lymphocyte proliferation, embryonic growth, and 
kidney development (Geiman et al., 2001; Geiman 
and Muegge, 2000).  
Loss leads to global DNA methylation changes 
including global hypomethylation at repetive 
sequences, as well as both hypo and 
hypermethylation of single copy genes (Myant et 
al., 2011; Tao et al., 2011b; Dunican et al., 2013; 
Yu et al., 2014).  
HELLS has been identified as a marker of 
mammalian stem cells with expression decreasing 
upon differentiation.  
Reduction in expression of HELLS leads to 
prolonged expresssion of stem cell genes 
implicating this protein as having a role in stem cell 
gene silencing (Xi et al., 2009).  
HELLS has been also implicated in DNA repair 
(Burrage et al., 2012).  
HELLS is additionally involved in meiosis with its 
loss leading to reduced proliferation and 
differentiation of germ cells with defects in 
synapsis (de la Fuente et al., 2006; Zeng et al., 
2011). 
Homology 
HELLS exhibits homology with other SNF2 family 
members like SNF2H, SNF2L, CHD1, CHD2, 
CHD3, CHD4, CHD5, CHD6, CHD7, CHD8, 
CHD9, BRG1, and BRAHMA. While other SNF2 
family members contain additional domains such as 
chromodomains, bromodomains, BRK, PHD, and 
RING fingers, HELLS protein does not. Because of 
this lack of additional domains, Lsh does not fit into 
any of the other subfamilies of SNF2 members but 
appears to represent a distinct subfamily of SNF2 
factors. By homology, it is most closely related to 
the CHD and SNF2H/L (ISWI) subfamily. 
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Mutations 
Note 
Hellstm1Kmu 
There are two mutant mouse models of HELLS. 
The original knockout mouse generated by the 
Muegge lab (Hellstm1Kmu) deleting the helicase 
domains of I, Ia, and part of two that are included in 
exons 6 and 7.  
These mutant mice die perinatally with embryonic 
growth retardation (Geiman et al., 2001). These null 
embryos have kidney defects such as necrosis and 
globule formation in tubules (Geiman et al., 2001). 
Murine embryonic fibroblasts display early 
senescence in culture and mitotic defects (Fan et al., 
2003).  
Since HELLS is highly expressed in developing 
and activated lymphoid tissue, lymphoid 
development and function was studied using a 
radiation chimera.  
Null embryos display lymphoid defects in 
thymocyte development with a partial blockage in 
transitioning from CD4/CD8 double negative to 
double positive T lymphocytes.  
This partial arrest in lymphocyte development leads 
to a reduction in mature T and B lymphocytes 
(Geiman et al., 2000).  
In addition, activation of lymphocytes leads to 
apoptosis intead of cell proliferation (Geiman et al., 
2000).  
Molecular studies on this mouse led to identifying 
HELLS as a gene necessary for DNA methylation 
and important for correct chromatin packaging and 
histone methylation (Dennis et al., 2001; Yan et al., 
2003b ; Huang et al., 2004; Myant et al., 2011; Tao 
et al., 2011b; Yu et al., 2014). 
Hellstm1Rarc 
Another mutant mouse model of Hells was 
developed in the Arceci lab designated Hellstm1Rarc. 
This mouse model was generated from a 
hypomorphic allele of HELLS by deleting exons 
10, 11, and 12 (Sun et al., 2004). The deleted 
section includes several helicase domains of 
HELLS (III, IV, and part of II) but not the ATPase 
domain. This mutant mouse also shows growth 
retardation but approximately 40% of mice survive 
to several weeks of age unlike the Muegge mouse 
model which die at birth. Additionally, these mice 
exhibit signs of premature aging with defects such 
as graying hair and balding, low fat deposition, and 
unstable gate among others (Sun et al., 2004). The 
premature aging defects seen in this mouse model 
are likely the result of replicative senescence caused 
by increased expression of the p16 tumor 
suppressor gene in these HELLS mutant mice. 
Molecular analysis demonstrated profound DNA 
methylation loss and aberrant expression of repeat 
sequences (Sun et al., 2004; Dunican et al., 2013). 
Implicated in 
Acute myelogenous leukemia, acute 
lymphoblastic leukemia 
Note 
When the HELLS gene was first characterized, it 
was found to be located in a break point region of 
the human genome frequently associated with 
leukemia at 10q23-10q24 (Geiman et al., 1998). 
Subsequently, an in-frame 75 ntd deletion in exon 
18 (variant 9) of the HELLS gene was found in 
57% of accute myelogenous leukemia and 37% of 
acute lymphoblastic leukemia patient samples 
tested but not in normal lymphoid tissue examined 
(Lee et al., 2000). This deletion leads to the loss of 
25 amino acids and includes part of one of the 
conserved SNF2 family helicase domain. This same 
variant was also detected in both normal and non-
small cell lung cancer patient samples raising the 
possibility that variant 9 is also expressed in some 
normal tissue (Yano et al., 2004). 
Erythroleukemia 
Note 
The mouse HELLS gene (Lsh) has been implicated 
in the development of erythroleukemia based on 
animal studies involving the original knockout 
mouse model (Hellstm1Kmu) (Fan et al., 2008). Since 
these mice die at birth, hematopoiesis was studied 
using a reconstitution model (Geiman et al., 2001). 
Hells -/- mice had defective hematopoiesis (Fan et 
al., 2008). In a subset of mice reconstituted with 
Hells-/- cells, erythroleukemia developed which is 
normally a rare spontaneous event in mice. Hells 
loss leads to hypomethylation of repetitive elements 
throughout the genome (Huang et al., 2004; 
Dunican et al., 2013). This hypomethylation was 
found to occur in these Hells null mouse 
hemaotopoietic progenitor cells at retroviral 
elements within the PU.1 oncogene leading to 
overexpression of the gene (Fan et al., 2008). 
Increased PU.1 gene expression is linked to 
erythroleukemia. 
Non-small cell lung cancer (NSCLC) 
Note 
A 44 ntd insertion between exons 3 and 4 (variant 
1) was detected in 26% of non-small cell lung 
cancer samples but in none of the normal tissue 
samples (Yano et al., 2004). This insertion through 
exon creation of a sequence of intronic origin is 
predicted to lead to premature termination of 
translation leading to a 97 amino acid protein. The 
truncated protein may act as a dominant negative 
protein. This truncated HELLS may also lose its 
normal nuclear localization since at least part of the 
nuclear localization signal (NLS) would be 
affected. 
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Head and neck cancer 
Note 
HELLS is a downstream target of the FOXM1 
transcription factor (Waseem et al., 2010). Both 
HELLS and FOXM1 have been found to be 
overexpressed in head and neck cancer such as 
oraopharyngeal squamous cell carcinoma (Janus et 
al., 2011). High expression of both genes correlates 
with tumor stage 3 or higher. Additionally, HELLS 
expression was found to increase in progression 
from normal to dysplasia and then squamous cell 
carcinoma and metastasis in head and neck cancer 
(Waseem et al., 2010). Because of this, HELLS has 
been proposed as a biomarker for early detection 
and progression of head and neck cancer. 
Additionally, HELLS is known to be involved in 
control of p16 tumor suppressor gene expression 
through repression with reduction in HELLS 
leading to increased p16 expression. FOXM1 also 
suppresses p16, likely through HELLS induction 
(Teh et al., 2012). This also leads to a DNA 
methylation profile in primary oral keratinocytes 
that is similar to human head and neck cancer (Teh 
et al., 2012). 
Breast cancer 
Note 
The HELLS gene has been found to be mutated in 
3% of invasive breast cancer samples. Most are an 
amplification or upregulation of the HELLS gene 
but there are also some that have deletion or 
downregulation (Colak et al., 2013). HELLS was 
proposed to be a possible marker for progression 
from pre-invasive ductal carcinoma in situ (DCIS) 
to invasive ductal carcinoma (IDC). Additionally, 
the HELLS gene is located in a copy number 
alteration chromosomal region (Colak et al., 2013). 
Furthermore, depletion of HELLS in a breast cancer 
cell line reduced DNA methylation at several tumor 
suppressor genes. This resulted in de-repression of 
genes involved in proliferation, and altered several 
growth characteristics of breast cancer cells in vitro 
including anchorage independent growth in soft 
agar and the ability to migrate in a wound healing 
assay (Tao et al., 2011a). 
Skin squamous cell carcinoma 
Note 
The role of HELLS in skin tumorigenesis was 
explored by overexpressing a deltaNp63alpha 
isoform of the p63 gene (Keyes et al., 2011). 
HELLS is a direct transcriptional target of 
deltaNp63alpha. HELLS had been implicated in 
senescence before by targeting the p16 tumor 
supressor gene. In this study, p16 was found not to 
be involved. Instead, increased deltaNp63alpha led 
to upregulation of HELLS expression. This caused 
senescence bypass, increased stem like cells and 
tumorigenesis in human primary keratinocytes. 
Melanoma 
Note 
HELLS was identified as a gene having elevated 
expression in aggressive metastatic tumor cells 
lines compared to cell lines from less aggressive 
primary tumors (Ryu et al., 2007).  
HELLS mRNA was also detected in the blood of 
patients with different stages of melanoma. The 
level of HELLS mRNA in patient blood was 
significantly higher in patients with metastatic 
melanoma than those with localized primary tumors 
(Kim et al., 2010).  
This work also found that HELLS expression in 
blood appears to be a better biomarker for 
metastatic melanoma than the currently used 
standard (Kim et al., 2010).  
These results suggest that HELLS may be a useful 
biomarker of melanoma presence and progression 
and a possible target for intervention. 
Prostate cancer 
Note 
The HELLS protein specifically interacts with 
E2F3, a transcription factor uniquely amplified in 
some human tumors.  
The expression of E2F3 is inversely correlated with 
patient survival. HELLS and E2F3 are co-
overexpressed in prostate carcinomas at the most 
aggressive stages.  
The association of HELLS and E2F3 occurs at 
several E2F target genes that control cell cycle 
entry.  
Depletion of HELLS in a prostate cancer cell line 
reduced the induction of E2F target genes and 
impaired growth suggesting that HELLS may 
contribute to the malignant progression of tumors 
(von Eyss et al., 2012). 
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